These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 30816473)

  • 1. Pioglitazone increases VEGFR3 expression and promotes activation of M2 macrophages via the peroxisome proliferator‑activated receptor γ.
    Zhang C; Zhang Y; Zhang C; Liu Y; Liu Y; Xu G
    Mol Med Rep; 2019 Apr; 19(4):2740-2748. PubMed ID: 30816473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential roles of cardiomyocyte and macrophage peroxisome proliferator-activated receptor gamma in cardiac fibrosis.
    Caglayan E; Stauber B; Collins AR; Lyon CJ; Yin F; Liu J; Rosenkranz S; Erdmann E; Peterson LE; Ross RS; Tangirala RK; Hsueh WA
    Diabetes; 2008 Sep; 57(9):2470-9. PubMed ID: 18511847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peroxisome proliferator-activated receptor-γ agonist pioglitazone fails to attenuate renal fibrosis caused by unilateral ureteral obstruction in mice.
    Zhang Y; Wang J; Zhou QD; Zhang CH; Li Q; Huang S; Zhan J; Wang K; Liu YY; Xu G
    J Huazhong Univ Sci Technolog Med Sci; 2016 Feb; 36(1):41-47. PubMed ID: 26838738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pioglitazone enhances cholesterol efflux from macrophages by increasing ABCA1/ABCG1 expressions via PPARγ/LXRα pathway: findings from in vitro and ex vivo studies.
    Ozasa H; Ayaori M; Iizuka M; Terao Y; Uto-Kondo H; Yakushiji E; Takiguchi S; Nakaya K; Hisada T; Uehara Y; Ogura M; Sasaki M; Komatsu T; Horii S; Mochizuki S; Yoshimura M; Ikewaki K
    Atherosclerosis; 2011 Nov; 219(1):141-50. PubMed ID: 21862012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peroxisome proliferator-activated receptor-gamma targeting nanomedicine promotes cardiac healing after acute myocardial infarction by skewing monocyte/macrophage polarization in preclinical animal models.
    Tokutome M; Matoba T; Nakano Y; Okahara A; Fujiwara M; Koga JI; Nakano K; Tsutsui H; Egashira K
    Cardiovasc Res; 2019 Feb; 115(2):419-431. PubMed ID: 30084995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pioglitazone decreased renal calcium oxalate crystal formation by suppressing M1 macrophage polarization via the PPAR-γ-miR-23 axis.
    Chen Z; Yuan P; Sun X; Tang K; Liu H; Han S; Ye T; Liu X; Yang X; Zeng J; Yan L; Xing J; Xiao K; Ye Z; Xu H
    Am J Physiol Renal Physiol; 2019 Jul; 317(1):F137-F151. PubMed ID: 31091119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphangiogenesis in renal fibrosis arises from macrophages via VEGF-C/VEGFR3-dependent autophagy and polarization.
    Zhang Y; Zhang C; Li L; Liang X; Cheng P; Li Q; Chang X; Wang K; Huang S; Li Y; Liu Y; Xu G
    Cell Death Dis; 2021 Jan; 12(1):109. PubMed ID: 33479195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Additive antifibrotic effects of pioglitazone and candesartan on experimental renal fibrosis in mice.
    Higashi K; Oda T; Kushiyama T; Hyodo T; Yamada M; Suzuki S; Sakurai Y; Miura S; Kumagai H
    Nephrology (Carlton); 2010 Apr; 15(3):327-35. PubMed ID: 20470302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pioglitazone-Mediated Peroxisome Proliferator-Activated Receptor γ Activation Aggravates Murine Immune-Mediated Hepatitis.
    Schulte R; Wohlleber D; Unrau L; Geers B; Metzger C; Erhardt A; Tiegs G; van Rooijen N; Heukamp LC; Klotz L; Knolle PA; Diehl L
    Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32260486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype.
    Yamamoto S; Zhong J; Yancey PG; Zuo Y; Linton MF; Fazio S; Yang H; Narita I; Kon V
    Atherosclerosis; 2015 Sep; 242(1):56-64. PubMed ID: 26184694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peroxisome Proliferator-Activated Receptor-γ Agonist Attenuates Vocal Fold Fibrosis in Rats via Regulation of Macrophage Activation.
    Kaba S; Kawai Y; Tanigami Y; Ohnishi H; Kita T; Yoshimatsu M; Omori K; Kishimoto Y
    Am J Pathol; 2022 May; 192(5):771-782. PubMed ID: 35189097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of peroxisome proliferator-activated receptor-γ ligands on in vitro and in vivo models of COPD.
    Lea S; Plumb J; Metcalfe H; Spicer D; Woodman P; Fox JC; Singh D
    Eur Respir J; 2014 Feb; 43(2):409-20. PubMed ID: 23794466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pioglitazone suppresses macrophage proliferation in apolipoprotein-E deficient mice by activating PPARγ.
    Murakami-Nishida S; Matsumura T; Senokuchi T; Ishii N; Kinoshita H; Yamada S; Morita Y; Nishida S; Motoshima H; Kondo T; Komohara Y; Araki E
    Atherosclerosis; 2019 Jul; 286():30-39. PubMed ID: 31096071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pioglitazone strengthen therapeutic effect of adipose-derived regenerative cells against ischemic cardiomyopathy through enhanced expression of adiponectin and modulation of macrophage phenotype.
    Mori D; Miyagawa S; Matsuura R; Sougawa N; Fukushima S; Ueno T; Toda K; Kuratani T; Tomita K; Maeda N; Shimomura I; Sawa Y
    Cardiovasc Diabetol; 2019 Mar; 18(1):39. PubMed ID: 30902059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of macrophage-dependent peroxisome proliferator-activated receptor γ signalling on adhesion formation after abdominal surgery in an experimental model.
    Hong GS; Schwandt T; Stein K; Schneiker B; Kummer MP; Heneka MT; Kitamura K; Kalff JC; Wehner S
    Br J Surg; 2015 Nov; 102(12):1506-16. PubMed ID: 26313905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pioglitazone attenuates aging-related disorders in aged apolipoprotein E deficient mice.
    Shen D; Li H; Zhou R; Liu MJ; Yu H; Wu DF
    Exp Gerontol; 2018 Feb; 102():101-108. PubMed ID: 29221940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective Role of Peroxisome Proliferator-Activated Receptor-γ in the Development of Intracranial Aneurysm Rupture.
    Shimada K; Furukawa H; Wada K; Korai M; Wei Y; Tada Y; Kuwabara A; Shikata F; Kitazato KT; Nagahiro S; Lawton MT; Hashimoto T
    Stroke; 2015 Jun; 46(6):1664-72. PubMed ID: 25931465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PPAR-γ agonists in polycystic kidney disease with frequent development of cardiovascular disorders.
    Nagao S; Yamaguchi T
    Curr Mol Pharmacol; 2012 Jun; 5(2):292-300. PubMed ID: 22122459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peroxisome Proliferator-Activated Receptor-γ Modulates the Response of Macrophages to Lipopolysaccharide and Glucocorticoids.
    Heming M; Gran S; Jauch SL; Fischer-Riepe L; Russo A; Klotz L; Hermann S; Schäfers M; Roth J; Barczyk-Kahlert K
    Front Immunol; 2018; 9():893. PubMed ID: 29867927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoxia reduces the expression and anti-inflammatory effects of peroxisome proliferator-activated receptor-gamma in human proximal renal tubular cells.
    Li X; Kimura H; Hirota K; Sugimoto H; Kimura N; Takahashi N; Fujii H; Yoshida H
    Nephrol Dial Transplant; 2007 Apr; 22(4):1041-51. PubMed ID: 17255125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.